Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 18, 2015 3:15 AM ET

Pharmaceuticals

Company Overview of Landsteiner Scientific, S.A. de C.V

Company Overview

Landsteiner Scientific, S.A. de C.V., a pharmaceutical company, engages in the research, development, manufacture, distribution, and marketing of healthcare products primarily in Mexico, the United States, and Europe. The company offers products in various therapeutic areas, including cardiology, endocrología, gynecology, nephrology, neurology, oncology, transplant, and urology. It also provides pain and inflammation products, including analgesic-anti-inflammatory and neuropathic pain products; anti-infective products, such as antibiotics, antifungal, and antiviral products; central nervous system products comprising antiemetic, depression, epilepsy, and haemorrheologic products; and metabol...

Av. Periférico Sur No. 4118

Piso 6

Col. Jardines De Pedregal

Mexico City, DF 01900

Mexico

Founded in 1998

Key Executives for Landsteiner Scientific, S.A. de C.V

Landsteiner Scientific, S.A. de C.V does not have any Key Executives recorded.

Landsteiner Scientific, S.A. de C.V Key Developments

Iroko Pharmaceuticals Inc. Signs New Strategic Agreement with Landsteiner Scientific, S.A. de C.V to Bring ZORVOLEX(R) to Mexico

Iroko Pharmaceuticals Inc. signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX(R) (diclofenac) capsules in Mexico. Landsteiner Scientific will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication. ZORVOLEX is approved by the United States Food and Drug Administration (FDA) for the management of mild to moderate acute pain and osteoarthritis pain. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the U.S.

Landsteiner Scientific, S.A. de C.V Presents at BioPharma Mexico 2013, Oct-30-2013 03:35 PM

Landsteiner Scientific, S.A. de C.V Presents at BioPharma Mexico 2013, Oct-30-2013 03:35 PM. Venue: Hyatt Regency Mexico City, Mexico. Speakers: Francisco Kuri Breña, Director of New Development.

Similar Private Companies By Industry

Company Name Region
CEVA KEMIA S. A. de C. V. Americas
Sandoz, S.A. de C.V. Americas
Quimica y Farmacia S.A. de C.V. Americas
Laboratorios Diba, S.A. Americas
Eli Lilly de Mexico, S.A. de C.V. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Landsteiner Scientific, S.A. de C.V, please visit www.landsteiner.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.